Trial Profile
Combination of Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer After Initial Treatment With Standard Therapy (CIRCUIT)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms CIRCUIT
- 07 Jul 2022 According to UMIN the status of the trial is completed, updated on 18th August' 2021 and NCT states that the trial status is unknown which was last updated on July 15, 2020. Hence, not adding unknown status comment. Please update when and where more information is available.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 18 Aug 2021 Status changed from active, no longer recruiting to completed.